ASSURA PLC - Assura achieves 200m disposal milestone

Assura achieves £200m disposal milestone

Assura plc
(Incorporated in England and Wales)
(Company Number: 09349441)
LEI number: 21380026T19N2Y52XF72
LSE Share Code: AGR
JSE Share Code: AHR
ISIN Code: GB00BVGBWW93
("Assura" or the "Company")

Assura achieves £200m disposal milestone

Assura plc, the UK's leading diversified healthcare REIT, is pleased to announce it has exchanged
on the disposal of seven assets for a gross consideration of £64 million.

The latest disposals mean that since the start of the financial year, the Company has sold 30 assets
for gross proceeds of £200 million at a weighted average net initial yield of 4.8%.

The net proceeds have been deployed in reducing the acquisition debt used to finance the £500
million private hospital portfolio acquired in August 2024 at 5.9% yield on cost.

The disposal announced today marks further progress in Assura's overall debt reduction plans and
the Company's proforma net LTV will reduce to 47%.

The sale also reinforces that the quality of the Company's portfolio and the resilience of its underlying
cash flows remain highly attractive to the investment market.

The disposal is immediately earnings enhancing as the cash receipts will be used to repay the
revolving credit facility.

The seven assets disposed of today have been sold into Assura's £250 million joint venture. Assura
retains a 20% equity interest in the joint venture resulting in net proceeds of £51 million. Following
this transaction, the joint venture has gross assets of £172 million. Assura continues to act as property
and asset manager to the joint venture, receiving management fees linked to the valuation of the
portfolio.

Jonathan Murphy, CEO, said:

"Reaching this £200 million milestone in our disposal programme means we are on track to achieve
our target of net debt to EBITDA below 9 times and LTV below 45% well ahead of the previously
outlined timetable. This accelerated delivery and our ability to achieve sales is testament to our
operational excellence and the quality and attractiveness of our property portfolio.

"The disposal programme was announced at the time of our transformational acquisition of high-
quality private hospital assets in August 2024. The acquisition has positioned Assura as a leader in a
structurally supported market, and has cemented our position as the UK's leading diversified
healthcare REIT offering an attractive investment opportunity into favourable long-term trends."

– Ends –


For more information, please contact:

Assura plc                                      Tel: 0161 515 2043
David Purcell, Investor Relations Director            Email: Investor@assura.co.uk


FGS Global                                            Tel: 0207 251 3801
Gordon Simpson                                        Email: Assura@fgsglobal.com
Grace Whelan


Notes to Editors
About Assura plc
Assura plc is the UK's leading diversified healthcare REIT. Assura enables better health outcomes
through its portfolio of more than 600 healthcare buildings, from which over six million patients are
served.
A UK REIT based in Altrincham, Assura is a constituent of the FTSE 250 and the EPRA* indices and
has a secondary listing on the Johannesburg Stock Exchange. As at 30 September 2024, Assura's
portfolio was valued at £3.2 billion and has a strong track record of growing financial returns and
dividends for shareholders.
At Assura we BUILD for health and as the first FTSE 250 certified B Corp we are committed to keeping
ESG at the heart of our strategy, creating Healthy Environments (E) and Healthy Communities (S)
and maintaining a Healthy Business (G).
Further information is available at www.assuraplc.com
*EPRA is a registered trademark of the European Public Real Estate Association


3 March 2025


Corporate Advisor and JSE Sponsor
Nedbank Corporate and Investment Banking, a division of Nedbank Limited

Date: 03-03-2025 09:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.